Department of Cardiovascular Disease, University of Rome, Tor Vergata, Rome, Italy.
Int J Cardiol. 2013 Sep 1;167(5):1783-93. doi: 10.1016/j.ijcard.2012.12.027. Epub 2013 Jan 5.
Although controversial, using prophylactic intra-aortic balloon pump (IABP) in patients undergoing high-risk percutaneous coronary intervention (PCI) has been reported to be effective by numerous registry studies. However, conflicting findings were observed in observational studies (Obs.) and randomised controlled trials (RCTs).
The purpose of this meta-analysis was to assess the impact of IABP on in-hospital deaths, major adverse cardiovascular events (MACCE), access-site complications and stroke in high-risk PCI cases from Obs. and RCTs published from 1st January, 1990 to 31st March, 2012 and indexed in PubMed.
We retrieved 1125 studies from the database; 11 studies compared the effects of IABP support, i.e., prophylactic administration (P-IABP) vs. no support (No-IABP), in high-risk patients undergoing PCI. These studies were included in the meta-analysis. We then calculated risk ratios (RRs) and risk differences (RDs) between the two groups of patients (P-IABP vs. No-IABP). We did not observe significant in-hospital mortality, MACCE, access-site complications or stroke differences in the RRs and RDs of the two groups.
The results suggest that PCI plus P-IABP support does not result in reduced in-hospital mortality or MACCE nor in significant higher access-site complications or stroke incidence compared with PCI alone in patients at high risk for peri-procedural PCI complications.
尽管存在争议,但许多注册研究报告称,在接受高危经皮冠状动脉介入治疗(PCI)的患者中预防性使用主动脉内球囊泵(IABP)是有效的。然而,观察性研究(Obs.)和随机对照试验(RCTs)观察到了相互矛盾的结果。
本荟萃分析的目的是评估 IABP 对 1990 年 1 月 1 日至 2012 年 3 月 31 日期间在 PubMed 中索引的观察性研究和 RCT 中高危 PCI 病例的住院内死亡率、主要不良心血管事件(MACCE)、入路部位并发症和卒中的影响。
我们从数据库中检索到 1125 项研究;11 项研究比较了 IABP 支持(预防性使用 [P-IABP])与不支持(无 IABP)在高危 PCI 患者中的效果。这些研究被纳入荟萃分析。然后,我们计算了两组患者(P-IABP 与 No-IABP)之间的风险比(RR)和风险差异(RD)。我们没有观察到两组患者的住院内死亡率、MACCE、入路部位并发症或卒中的 RR 和 RD 存在显著差异。
结果表明,与单独 PCI 相比,在高危患者中,PCI 加 P-IABP 支持并未导致住院内死亡率或 MACCE 降低,也未导致入路部位并发症或卒中发生率显著升高。